Cargando…

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review

BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirmosayyeb, Omid, Ghaffary, Elham Moases, Dehghan, Mohammad S., Ghoshouni, Hamed, Bagherieh, Sara, Barzegar, Mahdi, Shaygannejad, Vahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063869/
https://www.ncbi.nlm.nih.gov/pubmed/37008248
http://dx.doi.org/10.1177/11795735231167869
_version_ 1785017784363646976
author Mirmosayyeb, Omid
Ghaffary, Elham Moases
Dehghan, Mohammad S.
Ghoshouni, Hamed
Bagherieh, Sara
Barzegar, Mahdi
Shaygannejad, Vahid
author_facet Mirmosayyeb, Omid
Ghaffary, Elham Moases
Dehghan, Mohammad S.
Ghoshouni, Hamed
Bagherieh, Sara
Barzegar, Mahdi
Shaygannejad, Vahid
author_sort Mirmosayyeb, Omid
collection PubMed
description BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse myelitis (ATM), and MOGAD, have been reported following the COVID-19 infection during the current COVID-19 pandemic. On the other hand, it has been suggested that patients with MOGAD may be at greater risk for infection (particularly in the current pandemic). OBJECTIVE: In this systematic review, we gathered separately 1) MOGAD cases following COVID-19 infection as well as 2) clinical course of patients with MOGAD infected with COVID-19 based on case reports/series. METHODS: 329 articles were collected from 4 databases. These articles were conducted from inception to March 1(st), 2022. RESULTS: Following the screening, exclusion criteria were followed and eventually, 22 studies were included. In 18 studies, a mean ± SD time interval of 18.6 ± 14.9 days was observed between infection with COVID-19 and the onset of MOGAD symptoms. Symptoms were partially or completely recovered in a mean of 67 days of follow-up. Among 4 studies on MOGAD patients, the hospitalization rate was 25%, and 15% of patients were hospitalized in the intensive care unit (ICU). CONCLUSION: Our systematic review demonstrated that following COVID-19 infection, there is a rare possibility of contracting MOGAD. Moreover, there is no clear consensus on the susceptibility of MOGAD patients to severe COVID-19. However, obtaining deterministic results requires studies with a larger sample size.
format Online
Article
Text
id pubmed-10063869
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100638692023-03-31 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review Mirmosayyeb, Omid Ghaffary, Elham Moases Dehghan, Mohammad S. Ghoshouni, Hamed Bagherieh, Sara Barzegar, Mahdi Shaygannejad, Vahid J Cent Nerv Syst Dis COVID-19 – Advances, Challenges and Observations BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse myelitis (ATM), and MOGAD, have been reported following the COVID-19 infection during the current COVID-19 pandemic. On the other hand, it has been suggested that patients with MOGAD may be at greater risk for infection (particularly in the current pandemic). OBJECTIVE: In this systematic review, we gathered separately 1) MOGAD cases following COVID-19 infection as well as 2) clinical course of patients with MOGAD infected with COVID-19 based on case reports/series. METHODS: 329 articles were collected from 4 databases. These articles were conducted from inception to March 1(st), 2022. RESULTS: Following the screening, exclusion criteria were followed and eventually, 22 studies were included. In 18 studies, a mean ± SD time interval of 18.6 ± 14.9 days was observed between infection with COVID-19 and the onset of MOGAD symptoms. Symptoms were partially or completely recovered in a mean of 67 days of follow-up. Among 4 studies on MOGAD patients, the hospitalization rate was 25%, and 15% of patients were hospitalized in the intensive care unit (ICU). CONCLUSION: Our systematic review demonstrated that following COVID-19 infection, there is a rare possibility of contracting MOGAD. Moreover, there is no clear consensus on the susceptibility of MOGAD patients to severe COVID-19. However, obtaining deterministic results requires studies with a larger sample size. SAGE Publications 2023-03-29 /pmc/articles/PMC10063869/ /pubmed/37008248 http://dx.doi.org/10.1177/11795735231167869 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle COVID-19 – Advances, Challenges and Observations
Mirmosayyeb, Omid
Ghaffary, Elham Moases
Dehghan, Mohammad S.
Ghoshouni, Hamed
Bagherieh, Sara
Barzegar, Mahdi
Shaygannejad, Vahid
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
title Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
title_full Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
title_fullStr Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
title_full_unstemmed Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
title_short Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
title_sort myelin oligodendrocyte glycoprotein antibody-associated disease and covid-19: a systematic review
topic COVID-19 – Advances, Challenges and Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063869/
https://www.ncbi.nlm.nih.gov/pubmed/37008248
http://dx.doi.org/10.1177/11795735231167869
work_keys_str_mv AT mirmosayyebomid myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview
AT ghaffaryelhammoases myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview
AT dehghanmohammads myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview
AT ghoshounihamed myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview
AT bagheriehsara myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview
AT barzegarmahdi myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview
AT shaygannejadvahid myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview